GlassScriptPhysician profile
Tasha B Dickerson
NPI 1255412052
$10,564.83
in general payments reported to CMS, 2019-2025
49 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,756 · 2020: $1,234 · 2021: $2,152 · 2022: $1,735 · 2023: $1,693 · 2024: $865 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,680 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,679.61 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,179.77 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $1,154.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $893.84 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $677.34 | 2019-2025 | |
| Pfizer INC. | $677.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $616.40 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $597.47 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $458.14 | 2019-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $433.66 | 2021-2025 | |
| Valeritas, INC. | $318.62 | 2019 | |
| Vanda Pharmaceuticals INC. | $250.72 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $247.32 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.42 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $221.42 | 2021 | |
| Xeris Pharmaceuticals, INC. | $210.16 | 2021-2025 | Gvoke Hypopen |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tasha Dickerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.